Protagenic Therapeutics, Inc. (PTIX)
|Net Income (ttm)||-3.34M|
|Trading Day||June 18|
|Day's Range||2.94 - 3.73|
|52-Week Range||1.84 - 4.89|
Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?
These biotech penny stocks pushed up big today; but are they worth it? The post 4 Biotech Penny Stocks That You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...
Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on In...
Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq
New York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a publ...
Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering
New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a publ...
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
|IPO Date |
Jan 5, 2016
|Stock Exchange |
|Ticker Symbol |
The average 12-month stock price forecast for PTIX is 4.50, which is an increase of 53.06% from the latest price.